(BCPC) Balchem - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0576652004
Stock:
Total Rating 58
Risk 84
Buy Signal 0.21
| Risk 5d forecast | |
|---|---|
| Volatility | 23.0% |
| Relative Tail Risk | -7.44% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.19 |
| Alpha | -4.46 |
| Character TTM | |
|---|---|
| Beta | 0.480 |
| Beta Downside | 0.622 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.10% |
| CAGR/Max DD | 0.51 |
EPS (Earnings per Share)
Revenue
Description: BCPC Balchem
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 154.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 3.39 > 1.0 |
| NWC/Revenue: 18.24% < 20% (prev 16.37%; Δ 1.88% < -1%) |
| CFO/TA 0.13 > 3% & CFO 216.6m > Net Income 154.8m |
| Net Debt (117.4m) to EBITDA (263.5m): 0.45 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.3m) vs 12m ago -0.70% < -2% |
| Gross Margin: 35.74% > 18% (prev 0.35%; Δ 3538 % > 0.5%) |
| Asset Turnover: 63.19% > 50% (prev 60.54%; Δ 2.65% > 0%) |
| Interest Coverage Ratio: 21.37 > 6 (EBITDA TTM 263.5m / Interest Expense TTM 10.2m) |
Altman Z'' 6.48
| A: 0.11 (Total Current Assets 365.6m - Total Current Liabilities 176.4m) / Total Assets 1.71b |
| B: 0.66 (Retained Earnings 1.12b / Total Assets 1.71b) |
| C: 0.13 (EBIT TTM 218.3m / Avg Total Assets 1.64b) |
| D: 2.59 (Book Value of Equity 1.17b / Total Liabilities 450.1m) |
| Altman-Z'' Score: 6.48 = AAA |
Beneish M -2.94
| DSRI: 1.10 (Receivables 143.6m/119.7m, Revenue 1.04b/953.7m) |
| GMI: 0.99 (GM 35.74% / 35.25%) |
| AQI: 0.98 (AQ_t 0.60 / AQ_t-1 0.61) |
| SGI: 1.09 (Revenue 1.04b / 953.7m) |
| TATA: -0.04 (NI 154.8m - CFO 216.6m) / TA 1.71b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of BCPC shares?
As of March 01, 2026, the stock is trading at USD 181.43 with a total of 182,453 shares traded.
Over the past week, the price has changed by +5.91%, over one month by +9.23%, over three months by +16.86% and over the past year by +6.13%.
Over the past week, the price has changed by +5.91%, over one month by +9.23%, over three months by +16.86% and over the past year by +6.13%.
Is BCPC a buy, sell or hold?
Balchem has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy BCPC.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BCPC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 196.8 | 8.4% |
| Analysts Target Price | 196.8 | 8.4% |
BCPC Fundamental Data Overview February 26, 2026
P/E Trailing = 39.0722
P/E Forward = 29.2398
P/S = 5.5876
P/B = 3.7439
P/EG = 4.8341
Revenue TTM = 1.04b USD
EBIT TTM = 218.3m USD
EBITDA TTM = 263.5m USD
Long Term Debt = 154.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 3.82m USD (from shortTermDebt, last quarter)
Debt = 192.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 117.4m USD (from netDebt column, last quarter)
Enterprise Value = 5.91b USD (5.80b + Debt 192.0m - CCE 74.6m)
Interest Coverage Ratio = 21.37 (Ebit TTM 218.3m / Interest Expense TTM 10.2m)
EV/FCF = 27.30x (Enterprise Value 5.91b / FCF TTM 216.6m)
FCF Yield = 3.66% (FCF TTM 216.6m / Enterprise Value 5.91b)
FCF Margin = 20.88% (FCF TTM 216.6m / Revenue TTM 1.04b)
Net Margin = 14.93% (Net Income TTM 154.8m / Revenue TTM 1.04b)
Gross Margin = 35.74% ((Revenue TTM 1.04b - Cost of Revenue TTM 666.5m) / Revenue TTM)
Gross Margin QoQ = 35.62% (prev 35.68%)
Tobins Q-Ratio = 3.46 (Enterprise Value 5.91b / Total Assets 1.71b)
Interest Expense / Debt = 1.13% (Interest Expense 2.18m / Debt 192.0m)
Taxrate = 21.60% (10.8m / 50.0m)
NOPAT = 171.2m (EBIT 218.3m * (1 - 21.60%))
Current Ratio = 2.07 (Total Current Assets 365.6m / Total Current Liabilities 176.4m)
Debt / Equity = 0.15 (Debt 192.0m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = 0.45 (Net Debt 117.4m / EBITDA 263.5m)
Debt / FCF = 0.54 (Net Debt 117.4m / FCF TTM 216.6m)
Total Stockholder Equity = 1.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.43% (Net Income 154.8m / Total Assets 1.71b)
RoE = 12.31% (Net Income TTM 154.8m / Total Stockholder Equity 1.26b)
RoCE = 15.46% (EBIT 218.3m / Capital Employed (Equity 1.26b + L.T.Debt 154.0m))
RoIC = 11.92% (NOPAT 171.2m / Invested Capital 1.44b)
WACC = 7.47% (E(5.80b)/V(5.99b) * Re(7.69%) + D(192.0m)/V(5.99b) * Rd(1.13%) * (1-Tc(0.22)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.24%
[DCF] Terminal Value 83.00% ; FCFF base≈188.5m ; Y1≈232.5m ; Y5≈395.9m
[DCF] Fair Price = 227.6 (EV 7.49b - Net Debt 117.4m = Equity 7.37b / Shares 32.4m; r=7.47% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 81.42 | EPS CAGR: 6.62% | SUE: 2.55 | # QB: 3
Revenue Correlation: 75.74 | Revenue CAGR: 3.84% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.34 | Chg7d=+0.030 | Chg30d=+0.030 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=5.70 | Chg7d=+0.127 | Chg30d=+0.127 | Revisions Net=+1 | Growth EPS=+10.7% | Growth Revenue=+6.4%
EPS next Year (2027-12-31): EPS=5.99 | Chg7d=+0.050 | Chg30d=+0.050 | Revisions Net=+0 | Growth EPS=+5.1% | Growth Revenue=+4.4%
P/E Forward = 29.2398
P/S = 5.5876
P/B = 3.7439
P/EG = 4.8341
Revenue TTM = 1.04b USD
EBIT TTM = 218.3m USD
EBITDA TTM = 263.5m USD
Long Term Debt = 154.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 3.82m USD (from shortTermDebt, last quarter)
Debt = 192.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 117.4m USD (from netDebt column, last quarter)
Enterprise Value = 5.91b USD (5.80b + Debt 192.0m - CCE 74.6m)
Interest Coverage Ratio = 21.37 (Ebit TTM 218.3m / Interest Expense TTM 10.2m)
EV/FCF = 27.30x (Enterprise Value 5.91b / FCF TTM 216.6m)
FCF Yield = 3.66% (FCF TTM 216.6m / Enterprise Value 5.91b)
FCF Margin = 20.88% (FCF TTM 216.6m / Revenue TTM 1.04b)
Net Margin = 14.93% (Net Income TTM 154.8m / Revenue TTM 1.04b)
Gross Margin = 35.74% ((Revenue TTM 1.04b - Cost of Revenue TTM 666.5m) / Revenue TTM)
Gross Margin QoQ = 35.62% (prev 35.68%)
Tobins Q-Ratio = 3.46 (Enterprise Value 5.91b / Total Assets 1.71b)
Interest Expense / Debt = 1.13% (Interest Expense 2.18m / Debt 192.0m)
Taxrate = 21.60% (10.8m / 50.0m)
NOPAT = 171.2m (EBIT 218.3m * (1 - 21.60%))
Current Ratio = 2.07 (Total Current Assets 365.6m / Total Current Liabilities 176.4m)
Debt / Equity = 0.15 (Debt 192.0m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = 0.45 (Net Debt 117.4m / EBITDA 263.5m)
Debt / FCF = 0.54 (Net Debt 117.4m / FCF TTM 216.6m)
Total Stockholder Equity = 1.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.43% (Net Income 154.8m / Total Assets 1.71b)
RoE = 12.31% (Net Income TTM 154.8m / Total Stockholder Equity 1.26b)
RoCE = 15.46% (EBIT 218.3m / Capital Employed (Equity 1.26b + L.T.Debt 154.0m))
RoIC = 11.92% (NOPAT 171.2m / Invested Capital 1.44b)
WACC = 7.47% (E(5.80b)/V(5.99b) * Re(7.69%) + D(192.0m)/V(5.99b) * Rd(1.13%) * (1-Tc(0.22)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.24%
[DCF] Terminal Value 83.00% ; FCFF base≈188.5m ; Y1≈232.5m ; Y5≈395.9m
[DCF] Fair Price = 227.6 (EV 7.49b - Net Debt 117.4m = Equity 7.37b / Shares 32.4m; r=7.47% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 81.42 | EPS CAGR: 6.62% | SUE: 2.55 | # QB: 3
Revenue Correlation: 75.74 | Revenue CAGR: 3.84% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.34 | Chg7d=+0.030 | Chg30d=+0.030 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=5.70 | Chg7d=+0.127 | Chg30d=+0.127 | Revisions Net=+1 | Growth EPS=+10.7% | Growth Revenue=+6.4%
EPS next Year (2027-12-31): EPS=5.99 | Chg7d=+0.050 | Chg30d=+0.050 | Revisions Net=+0 | Growth EPS=+5.1% | Growth Revenue=+4.4%